Literature DB >> 17635733

Cancer and thrombosis: from molecular mechanisms to clinical presentations.

H R Buller1, F F van Doormaal, G L van Sluis, P W Kamphuisen.   

Abstract

Although the bidirectional association between cancer and venous thromboembolism (VTE) has been known for almost two centuries, recent advances in our understanding of the clinical, laboratory, and epidemiologic aspects of this association have created a renewed interest in this topic. This review consists of two parts. The first part discusses the occurrence, determinants and significance of VTE in those with cancer, as well as the risk of developing and the possible need to detect cancer in those presenting with VTE. The second part reviews the role of hemostatic constituents (coagulation and fibrinolytic proteins and platelets) in promoting growth and progression of cancer, as well as the effects and possible mechanisms of the low molecular weight heparins (LMWH) in this process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635733     DOI: 10.1111/j.1538-7836.2007.02497.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  43 in total

1.  Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.

Authors:  Ana Custodio; Antonio J López-Farré; José J Zamorano-León; Petra J Mateos-Cáceres; Carlos Macaya; Trinidad Caldés; Miguel de la Hoya; Elena Olivera; Javier Puente; Eduardo Díaz-Rubio; Pedro Pérez-Segura
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-07       Impact factor: 4.553

2.  Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Garth W Tormoen; Todd H Wagner; Parag Mallick; Owen J T McCarty
Journal:  Converg Sci Phys Oncol       Date:  2017-05-17

3.  Association between Level of Tumor Markers and Development of VTE in Patients with Pancreatic, Colorectal and Ovarian Ca: Retrospective Case- Control Study in Two Community Hospitals.

Authors:  Nelly Awkar; Sawsan Amireh; Srijana Rai; Hamid Shaaban; Gunwant Guron; Michael Maroules
Journal:  Pathol Oncol Res       Date:  2017-05-04       Impact factor: 3.201

4.  Pulmonary embolism, myocardial infarction, and ischemic stroke in lung cancer patients: results from a longitudinal study.

Authors:  Myrthe P P van Herk-Sukel; Sumitra Shantakumar; Fernie J A Penning-van Beest; Pieter W Kamphuisen; Christof J Majoor; Lucy I H Overbeek; Ron M C Herings
Journal:  Lung       Date:  2013-06-27       Impact factor: 2.584

Review 5.  Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Authors:  Hikmat Abdel-Razeq; Asem Mansour
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

6.  Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients.

Authors:  Jorge I F Salluh; Márcio Soares; Ernesto De Meis
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

Review 7.  Epidemiology of cancer-related venous thromboembolism.

Authors:  Ted Wun; Richard H White
Journal:  Best Pract Res Clin Haematol       Date:  2009-03       Impact factor: 3.020

8.  Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model.

Authors:  T C Carneiro-Lobo; S Konig; D E Machado; L E Nasciutti; M F Forni; I M B Francischetti; M C Sogayar; R Q Monteiro
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

Review 9.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

10.  Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea.

Authors:  Inken Groth; Niels Grünewald; Susanne Alban
Journal:  Glycobiology       Date:  2008-12-23       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.